Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex to Hold Annual Meeting on April 11, 2011

April 6, 2011

Anavex Screening Healthy Volunteers for Phase I, First-in-Human Clinical Study in Alzheimer’s disease

March 31, 2011

Anavex Management to Hold Live Investor Conference Call Today at 4:30PM ET

March 16, 2011

Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

March 15, 2011

Anavex Appoints Dr. Jeffrey Cummings to its Scientific Advisory Board

March 1, 2011

Anavex Appoints Independent Director

February 24, 2011

Anavex Appoints Dr. Rachelle Doody to Scientific Advisory Board

February 23, 2011

Anavex Adds Dr. Paul Aisen to Scientific Advisory Board

February 16, 2011

Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law

January 18, 2011

Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease and Anavex’s Phase I Clinical Program as “Trial of the Year”

January 6, 2011

Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease

December 21, 2010

Anavex Appoints David Tousley as CFO

September 30, 2010
1
23456789101112131415161718192021222324252627
…2829303132…
333435363738394041
42

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top